Sign up for free.
The Synbias Pharma/GeminiPharmChem Group, consisting of Synbias Pharma AG in Switzerland and Gemini PharmChem Mannheim GmbH in Germany, is a leading specialist for the development and manufacturing of highly potent Active Pharmaceutical Ingredients (APIs), which are primarily used in cancer treatment.[1][2]
The portfolio includes Anthracyclines (such as Epirubicin and Doxorubicin), Nucleosides (e.g. Cladribine) as well as plant alkaloids. As the world's leading supplier of anthracycline antibiotics, the company holds 30–50% of the global market.[1][3] The APIs exceed pharmacopoeial standards: For Epirubicin and Doxorubicin, impurities (except Doxorubicinone) are limited to 0.10% – significantly stricter than the 0.5% limit of the European Pharmacopoeia. This ensures higher purity, stability and shelf life.[3] Approximately 200 kg of APIs are delivered annually in batches of 100 g to 15 kg to customers in 21 countries on 5 continents.[1]
In addition to commercial APIs, the group offers comprehensive CDMO services (Contract Development and Manufacturing Organization) for all phases of drug development – from clinical trials to commercial production. These include reference standards for quality controls and innovative synthesis routes for New Chemical Entities (NCEs).[1][4][5] Current R&D pipelines focus on Cladribine (for leukemia and multiple sclerosis) as well as premix formulations for easier dosing.[6]
The quality system meets cGMP standards and is inspected by authorities such as FDA, Swissmedic, ANVISA and German authorities (inspections 2012–2025).[1][2] Global regulatory documents such as US-DMF, CEP, C-DMF and J-MF are available.[3]
The Mission is: "Advance Global Health" through innovative APIs for a healthier future. Core values are excellence in oncology, reliability, innovation and customer-focused service. The company is characterized by competent employees, customized solutions and a leading position in niche markets.[1][2][7] It supports customers with regulatory submissions and emphasizes compliance as well as the highest standards for efficacy and safety.[2]
Although explicit sustainability initiatives are not described in detail, the focus on efficient, stable APIs with minimal impurities indirectly contributes to resource conservation and reduction of transport burdens.[3] The state-of-the-art facilities and the dedicated team of experts drive continuous progress in cancer research.[6][7]
With cutting-edge research and global reach, Synbias Pharma/GeminiPharmChem positions itself as an indispensable partner for pharmaceutical innovators – for better therapies tomorrow.[1][2]
(Total length: approx. 2480 characters incl. spaces)
